Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: Improved 3-year graft and patient survival in recent era

Transplantation

Volumn 87, Issue 11, 2009, Pages 1712-1719

  Gralla, Jane ^a   Wiseman, Alexander C ^b  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Graft survival; Kidney transplantation; Mycophenolate mofetil; Sirolimus; Tacrolimus

Indexed keywords

ALEMTUZUMAB; BACTRIM SS; BASILIXIMAB; CORTICOSTEROID; COTRIMOXAZOLE; GANCICLOVIR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BK VIRUS; BK VIRUS NEPHROPATHY; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EXPOSURE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEMATOCRIT; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES AFTER TRANSPLANT; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL;

ADULT; CADAVER; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; SURVIVAL RATE; TACROLIMUS; TISSUE DONORS;

EID: 67649616484     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a60431     Document Type: Article

References (30)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
2. Meier-Kriesche H-U, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
3. Meier-Kriesche HU, Li S, Gruessner RWG, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111.
4. Srinivas TR, Schold JD, Guerra G, et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7: 586.
5. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5: 2273.
6. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/ sirolimus in renal transplantation: Three-year analysis. Transplantation 2006; 81: 845.
7. Gallon L, Perico N, Dimitrov BD, et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 2006; 6: 1617.
8. Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 2005; 80: 303.
9. Vitko S, Wlodarczyk Z, Kyllonen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study. Am J Transplant 2006; 6: 531.
10. Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol2008; 19: 1411.
11. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234.
12. Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4: 2001.
13. Maiorano A, Stallone G, Schena A, et al. Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation 2006; 82: 908.
14. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007; 117: 2553.
15. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128.
16. Andoh TF, Lindsley J, Franceschini N, et al. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation1996; 62: 311.
17. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059.
18. Ninova D, Covarrubias M, Rea DJ, et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: Differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. Transplantation 2004; 78: 338.
19. Shihab FS, Bennett WM, Yi H, et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65: 1262.
20. Augustine JJ, Chang PC, Knauss TC, et al. Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. Transplantation 2006; 81: 1004.
21. Kaplan B, Schold J, Srinivas T, et al. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant 2004; 4: 1709.
22. Lloberas N, Torras J, Alperovich G, et al. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant 2008; 23: 3111.
23. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953.
24. Mulay AV, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant2005; 5: 1748.
25. Larson TS, Dean PG, Stegall MD, et al. Complete Avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
26. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation.NEngl J Med 2007; 357: 2562.
27. McTaggart RA, Tomlanovich S, Bostrom A, et al. Comparison of outcomes after delayed graft function: Sirolimus-based versus other calcineurin- inhibitor sparing induction immunosuppression regimens. Transplantation 2004; 78: 475.
28. Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004; 15: 228.
29. Smith KD, Wrenshall LE, Nicosia RF, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14: 1037.
30. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.